Patricia Carr Sells 4,813 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr sold 4,813 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $140.23 on Thursday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $8.52 billion, a PE ratio of 19.75, a P/E/G ratio of 1.04 and a beta of 0.56. The stock has a 50 day moving average price of $127.64 and a 200 day moving average price of $119.71.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Barclays restated an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $182.47.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Mackenzie Financial Corp increased its stake in Jazz Pharmaceuticals by 493.3% during the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock worth $2,498,000 after acquiring an additional 16,867 shares during the last quarter. Forum Financial Management LP acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth $245,000. GF Fund Management CO. LTD. acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth $156,000. MidWestOne Financial Group Inc. increased its stake in Jazz Pharmaceuticals by 10.4% during the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock worth $2,998,000 after acquiring an additional 2,284 shares during the last quarter. Finally, Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.